




CV Template of KATRD International Conference 2021

Name	Satoshi Ikeda			
First Name	Satoshi	Last Name	Ikeda	
Country	Japan			
Organization	Kanagawa Cardiovascular and Respiratory Center			
Current Position	Chief Physician			

Educational Background

2019 Ph.D. Department of Diagnostic Pathology, Yokohama City University
2007 M.D. Kanazawa University School of Medicine.

Professional Experiences

2015- Chief Physician in Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
2012-2015 Medical Staff in Respiratory Medicine, Kurashiki Central Hospital
2009-2012 Senior Resident in Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center
2007-2009 Junior Resident in Internal Medicine, Yokohama Sakae Kyosai Hospital
2007 Passed the Examination of National Board

Professional Organizations

Societies:

- The Japanese Respiratory Society (Board Certified)
- Japanese Society of Medical Oncology (Board Certified)
- Japanese Board of Cancer Therapy (Board Certified)
- The Japan Society for Respiratory Endoscopy (Board Certified)
- The Japanese Society of Internal Medicine (Board Certified)
- American Thoracic Society
- The Asian Pacific Society of Respirology
- The Japan Lung Cancer Society
- American Society of Clinical Oncology

Committee:

- West Japan Oncology Group [WJOG] young Investigators club for Next Generations, Steering Committee
- Thoracic Oncology Research Group [TORG], Clinical Trial Committee, Young Researcher Development Committee
- The Japanese Lung Cancer Society, Working Group on Educational Programs



Main Scientific Publications

(First author)

1. Ikeda S, Misumi T, Izumi S, et al. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: A multicenter, retrospective, propensity score-matched study. *Sci Rep.* 2021 May 21;11(1):10727.
2. Ikeda S, Kato T, Kenmotsu H, et al. Immune Checkpoint Inhibitor for Non-Small Cell Lung Cancer with Comorbid Interstitial Pneumonia; A Prudent Stance Required (Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis). *Eur J Cancer.* 2021 May 4:S0959-8049(21)00217-3. Online ahead of print.
3. Ikeda S, Kato T, Kenmotsu H, et al. A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonias. *J Thorac Oncol.* 2020;15(12):1935-1942.
4. Ikeda S, Ozawa Y, Harada K, et al. Importance of doctor-initiated management of the balance between work and treatment for lung cancer patients: results of a nationwide survey by the Japan Lung Cancer Society. *Cancer Med.* 2020 Jul 13;9(17):6186-95.
5. Ikeda S, Ogura T, Kato T, et al. Rationale and Protocol Design for the TORG1835 / NEXT-SHIP study: A Phase II Study of Carboplatin, Etoposide and Nintedanib for Unresectable Limited / Extensive Disease Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis. *Ther Adv Med Oncol.* 2020 May 18;12:1758835920923431.
6. Ikeda S, Kato T, Kenmotsu H, et al. A phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936 / AMBITIOUS study. *Ther Adv Med Oncol.* 2020 May 8;12:1758835920922022.
7. Ikeda S, Arai H, Sekine A, et al. Anterior mediastinal amyloidosis mimics thymic carcinoma. *JTO Clin Res Rep.* 2020 Apr. Epub 2020 April 11.
8. Ikeda S, Yoshioka H, Kaneda T, et al. A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small- Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302. *Oncology.* 2019;97(6):327-333.
9. Ikeda S, Sekine A, Baba T, et al. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis. *BMC Pulm Med.* 2019 Apr 11;19(1):78.
10. Ikeda S, Sekine A, Baba T, et al. Low starting-dosage of nintedanib for the reduction of early termination. *Respir Investig.* 2019 May;57(3):282-285.
11. Ikeda S, Sekine A, Baba T, et al. Secondary pulmonary alveolar proteinosis predominant in the transplanted lung in patients with idiopathic interstitial pneumonia: an autopsy case. *J Thorac Dis.* 2018 May;10(5):E351-E354.
12. Ikeda S, Kato T, Ogura T, et al. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016. *BMC Cancer.* 2018 Mar 2;18(1):241.
13. Ikeda S, Yoshioka H, Ikeo S, et al. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status. *BMC Cancer.* 2017 Nov 28;17(1):797.
14. Ikeda S, Sekine A, Baba T, et al. Low body surface area predicts hepatotoxicity of



- nintedanib in patients with idiopathic pulmonary fibrosis. *Sci Rep.* 2017 Sep 7;7(1):10811.
15. Ikeda S, Sekine A, Baba T, et al. Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience. *Respir Investig.* 2017 Jan;55(1):51-54.
 16. Ikeda S, Sekine A, Baba T, et al. Abundant immunoglobulin (Ig)G4-positive plasma cells in interstitial pneumonia without extrathoracic lesions of IgG4-related disease: is this finding specific to IgG4-related lung disease? *Histopathology.* 2017 Jan;70(2):242-252.
 17. Ikeda S, Sekine A, Baba T, et al. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report. *BMC Pulm Med.* 2016 Mar 3;16:38.
 18. Ikeda S, Arita M, Morita M, et al. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split? *BMC Pulm Med.* 2015 Dec 9;15:159.
 19. Ikeda S, Arita M, Misaki K, et al. Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study. *BMC Pulm Med.* 2015 Jul 30;15:78.
 20. Ikeda S, Arita M, Misaki K, et al. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. *Springerplus.* 2015 May 28;4:240.
 21. Ikeda S, Arita M, Ikeo S, et al. Chronological assessment of airway lesions in relapsing polychondritis by positron emission tomography. *Intern Med.* 2015;54(9):1099-102.
 22. Ikeda S, Yoshioka H, Arita M, et al. Interstitial lung disease induced by alectinib (CH5424802/RO5424802). *Jpn J Clin Oncol.* 2015 Feb;45(2):221-4. doi: 10.1093/jjco/hyu183.
 23. Ikeda S, Sekine A, Kato T, et al. Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case. *Jpn J Clin Oncol.* 2014 May;44(5):497-500.